EarningsQ3 2026 Earnings Report
MX:BDX Q3 2026 EPS Results
Actual EPS$54.83
Consensus EPS$53.32
Beat/MissBeat by +$1.51
One Year Ago EPS$49.09
MX:BDX Q3 2026 Revenue Results
Actual Revenue$84.59B
Expected Revenue$82.96B
Beat/MissBeat by +$1.63B
YoY Revenue Growth-9.55%
Earnings Announcement Details
QuarterQ3 2026
Date08/06/2026
TimeBefore Open
Conference CallThursday, August 6, 2026
MX:BDX Upcoming Earnings
Becton Dickinson's next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:BDX Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong execution across BD's focused med‑tech portfolio: revenue and adjusted EPS beat expectations, growth platforms showed double-digit expansion, productivity and cash flow improved materially, and the company raised EPS guidance. Headwinds are defined and manageable — chiefly Alaris remediation, tariffs, vaccine weakness in China and some margin pressure versus the prior year — and management laid out clear mitigation actions (pricing, productivity, commercial investments, AI for supply chain). Overall the positives materially outweigh the negatives.Company Guidance
Revenue Outperformance
Q3 revenue of $5.0 billion, up 4.4% year-over-year (FX-neutral), ahead of expectations and driving an update to full-year revenue guidance toward the high end of the low single-digit range.
EPS and Profitability Beats
Adjusted EPS of $3.23, up 4.9% year-over-year and ahead of expectations; adjusted operating margin of 24.9% supported by productivity and mix benefits.
Broad-Based Portfolio Strength
More than 90% of the portfolio delivered high single-digit growth; several growth platforms achieved double-digit growth (biologic drug delivery, advanced patient monitoring, PureWick, advanced tissue regeneration).
Strong Growth in Key Segments
Segment performance included BioPharma Systems +5.2% (ex-vaccines mid-teens growth), Interventional +5.5%, Connected Care +4.4% (APM double-digit), Medical Essentials +3.2%, specimen management high single-digit and U.S. MDS strong with utilization/share gains.
Commercial Momentum and Share Gains
Alaris share gains of >200 basis points year-to-date in Connected Care; incremental commercial investments estimated to have contributed ~100–150 basis points to APM growth this year; ~100 agreements signed across GLP-1 programs in biologics.
Operational Execution & Productivity
BD Excellence delivered ~8% gross productivity improvement in plants this quarter, service levels above 90%, record-low back orders, and continued plant consolidations, raw material savings and waste reduction.
Cash Flow & Capital Return
Year-to-date free cash flow of $1.7 billion, up 45% versus prior year; returned $3.1 billion to shareholders YTD (~$2.3B share repurchases, ~$0.9B dividends); net leverage ~2.9x with a 2.5x long-term target.
Focused Innovation Launches
New product launches and early commercial traction: Liverty TIPS Stent Graft (Europe), Elyra Thulium Fiber Laser System (endourology), Acumen IQ Plus Finger Cuff and Smart Pressure Controller (noninvasive monitoring), and Vystra injection pen launch for semaglutide in Brazil.
MX:BDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed